Baptist Health South Signs Medline as its Exclusive Distributor for Medical Products

Medline today announced a multi-year prime vendor partnership with Florida-based Baptist Health South Florida.

The two organizations will partner to identify new strategies for enhancing data-driven operational and clinical efficiencies. As the system’s primary supplier, Medline will exclusively provide an extensive portfolio of essential medical supplies and solutions across the health system’s 12 hospitals and more than 200 outpatient centers and physician practices.

“We strive to be a world-class, value-based supply chain that drives financial and operational excellence for our system, which is a goal further supported by our partnership with Medline,” said George S. Godfrey, corporate vice president and chief supply chain officer at Baptist Health South Florida. “From the beginning, Medline has been open and receptive to exploring together new ways to better leverage technology to streamline and advance operations for our industry.”

Known for its industry-leading supply chain operations, Baptist Health South Florida will partner with Medline to optimize supply chain processes by leveraging data and technology to eliminate non-value-added activities and enhance financial and operational performance. As part of the strategic relationship, Baptist Health South Florida will have the ability to integrate key metrics such as item utilization, contract compliance, price accuracy, and spend by product categories through a collaborative analytics-integration process. The two organizations are committed to developing new ways to enhance supply chain operations and patient care through data.

“When Medline becomes an extension of a team, as we have with Baptist Health South Florida, our shared commitment to data accuracy and accountability enables us both to reach new levels of actionable insights,” says Jen Cerami, executive account director at Medline. “The Baptist Health South Florida team challenges me to think differently. I am excited to evolve together as we tackle supply chain challenges and create customized, cutting-edge solutions to help healthcare run better.”

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”